“The most interesting trial is the PROMISE trial. Since the clinical outcomes are so low in the patient population that was tested with both computed tomography angiography as well as the functional assessment group, one wonders if we have to do any kind of testing at all … Further randomized trials comparing any kind of testing versus not testing would be beneficial in answering the question.” — Jaya Mallidi, MD

“The most controversial trial for me is the PARTNER trial, showing that the transcatheter aortic valve replacement is an effective alternative to surgical aortic valve replacement for high-risk patients with aortic stenosis. This trial is already making changes in daily practice because of the standard of care.” — Olamide Oladipo, DO

“The Myocardial Perfusion Multi-Center Study Regarding Fractional Flow Reserve (FFR). The FFR technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis is supposed to differentiate within significant and insignificant ischemia. I would say that this trial’s findings definitely affect daily practice.” — Kishore Sadanand, MBBS

“From all the trials discussed at ACC.15, the one that caught my attention was the PEGASUS-TIMI trial. The trial showed that stable heart attack patients prescribed ticagrelor in addition to low-dose aspirin have lower risks of experiencing a secondary cardiac event, death or stroke, even after one year. This trial is setting a better understanding on this.” — Timothy Fendler, MD

Keywords: Angiography, Aortic Valve, Aortic Valve Stenosis, Cardiac Catheterization, Coronary Stenosis, Standard of Care, Stroke, Tomography, Transcatheter Aortic Valve Replacement

< Back to Listings